Medications
Advanced ovarian cancer treatment approved
A targeted treatment for advanced ovarian cancer has been approved for use on the NHS in England and will be paid for by the Cancer Drugs Fund.
Oct 14, 2019
0
3
News tagged with rucaparib
Medications
New class of drug gives hope to some ovarian cancer patients
A study published today in Nature Communications shows that the drug rucaparib has been effective in treating certain types of ovarian cancers if used early in treatment, after a diagnosis, and before the cancer cells build ...
May 4, 2021
0
32
Oncology & Cancer
Advanced ovarian cancer drug gets initial 'no' for NHS in England
A targeted drug with potential to slow the progress of ovarian cancer has been rejected for use on the NHS in England.
Aug 12, 2019
0
12
Medications
Rucaparib efficacious in metastatic castration-resistant prostate cancer
For patients with metastatic castration-resistant prostate cancer, treatment with rucaparib is associated with significantly longer duration of imaging-based progression-free survival compared with a control medication, according ...
Feb 17, 2023
0
17
Oncology & Cancer
PARP inhibitor shrinks tumors in pancreatic cancer patients with mutations
More than two-thirds of pancreatic cancer patients harboring genetic mutations saw their tumor stop growing or shrink substantially after being switched from intensive chemotherapy to the PARP inhibitor rucaparib as a maintenance ...
May 10, 2021
0
21
Medications
Maintenance therapy with rucaparib shows clinical responses in a subgroup of patients with pancreatic cancer
Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) was well tolerated and provided clinical responses among patients with advanced BRCA- or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy, ...
Apr 2, 2019
0
1
Medications
New drug combination shows clinical activity for patients with prostate cancer
New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer (mCRPC). ...
Sep 20, 2021
0
8
